HomeNOV • ETR
add
Novo Nordisk A/S
Previous close
€41.93
Day range
€40.58 - €41.58
Year range
€35.76 - €90.46
Market cap
167.49B USD
Avg Volume
550.88K
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
In the news
Financials
Income Statement
Revenue
Net income
| (DKK) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 79.14B | -7.63% |
Operating expense | 29.73B | 12.96% |
Net income | 26.89B | -4.74% |
Net profit margin | 33.98 | 3.13% |
Earnings per share | 6.04 | -4.73% |
EBITDA | 36.66B | -23.44% |
Effective tax rate | 21.34% | — |
Balance Sheet
Total assets
Total liabilities
| (DKK) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 26.96B | 2.49% |
Total assets | 542.90B | 16.60% |
Total liabilities | 348.86B | 8.29% |
Total equity | 194.05B | — |
Shares outstanding | 4.44B | — |
Price to book | 0.96 | — |
Return on assets | 16.70% | — |
Return on capital | 29.56% | — |
Cash Flow
Net change in cash
| (DKK) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 26.89B | -4.74% |
Cash from operations | 7.62B | -38.06% |
Cash from investing | -42.81B | 53.07% |
Cash from financing | 29.47B | -20.00% |
Net change in cash | -5.62B | 86.41% |
Free cash flow | -34.95B | -1,011.09% |
About
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
Founded
Dec 21, 1923
Headquarters
Website
Employees
69,150